US 12,258,389 B2
Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
Erik D'Hondt, Bazel (BE); and Miguel Ángel Molina Vila, Badalona (ES)
Assigned to In3Bio Ltd., Hamilton (BM)
Filed by In3Bio Ltd., Hamilton (BM)
Filed on Jun. 25, 2021, as Appl. No. 17/358,788.
Application 17/358,788 is a continuation of application No. 15/073,021, filed on Mar. 17, 2016.
Claims priority of provisional application 62/160,183, filed on May 12, 2015.
Prior Publication US 2022/0041704 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/7084 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/7084 (2013.01); A61K 39/00 (2013.01); A61K 39/001104 (2018.08); A61K 39/001131 (2018.08); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01)] 7 Claims
 
1. A method of treating a patient suffering from a non-small cell lung cancer (NSCLC) that is responsive to treatment with an Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) and driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR) with a combination therapy, comprising:
administering to the patient a therapeutically effective amount of the EGFR-TKI and an immunogenic polypeptide comprising Epidermal Growth Factor (EGF) at an amount effective to generate an immune response against the EGF via active immunization,
wherein the EGFR-TKI is administered according to a continuous regimen based on an average daily dose in the range of 10 mg to 150 mg and the immunogenic polypeptide is co-administered according to a therapeutically effective amount,
wherein the EGFR-TKI is selected from the group consisting of gefitinib, erlotinib, and pharmaceutically acceptable salts thereof.